Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI
NCT ID: NCT00780858
Last Updated: 2015-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
662 participants
OBSERVATIONAL
2008-10-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles
NCT01286051
Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation
NCT03300960
Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
NCT00954811
Early Follicular Supplementation of Ganirelix in IVF 2004
NCT00461422
Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm.
NCT07110285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ganirelix
Patients with premature lutenization (progesterone \>1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
Ganirelix
Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
Control
Patients without premature lutenization (progesterone \>1,2 ng/ml) underwent a only one IUI.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ganirelix
Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* not eligible for IUI (patent tubes, \> 3 million capacitated spermatozoa)
* 4 previous IUI cycles
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVI Madrid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan A Garcia-Velasco
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan antonio García-Velasco, MD
Role: PRINCIPAL_INVESTIGATOR
IVI Madrid
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVI-Madrid
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kosmas IP, Tatsioni A, Kolibianakis EM, Verpoest W, Tournaye H, Van der Elst J, Devroey P. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril. 2008 Aug;90(2):367-72. doi: 10.1016/j.fertnstert.2007.06.064. Epub 2007 Oct 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVIMAD-JMS-09-2008-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.